Extended Data Fig. 10: Multipotency score and outcome in B-ALL.

a-f) OS and EFS Kaplan–Meier plots evaluating the multipotency score within genomic risk group categories (a,b), clinical risk groups (c,d) and MRD categories (e,f). Patients were assigned to high (red) and low (blue) multipotency score categories based on a median split. Hazard ratios and 95% confidence intervals for high vs low multipotency score are shown within each category. P values were derived from a Wald test. Sample sizes for genomic risk: Favorable (Low = 283, High = 258), Intermediate (Low = 156, High = 117), Unfavorable (Low = 66, High = 108), Unclassified (Low = 15, High = 36). Sample sizes for clinical risk: Childhood Standard Risk (Low = 230, High = 122), Childhood High Risk (Low = 250, High = 273), Adolescent/Young Adult (Low = 31, High = 109). Sample sizes for MRD: Negative (Low = 373, High = 277), Positive (Low = 90, High = 175). g,h) Association of B-ALL developmental states and of multipotency score with OS and EFS outcomes within 47 pediatric BCR::ABL1 patients (g) and 41 adult BCR::ABL1 patients from Kim et al.¹⁴ (h). For each developmental state (n = 47 in panel g, n = 41 in panel h). Hazard ratios from multivariable Cox regression, adjusting for age, sex, WBC, clinical risk group and genomic subtype, with overall survival and event-free survival are reported for each standard deviation increase in inferred abundance. Error bars depict the 95% confidence interval of the hazard ratio for each variable of interest.